Remarkable new findings about the sugar stores in neurons have unlocked an entire new method of treating Alzheimer's disease ...

Diabetics are more likely to develop Alzheimer’s than the general public. Could a popular diabetes and weight-loss drug also ...

The exact numbers depended on the type of medication patients took, but the risk of developing Alzheimer’s was up to 70 ...

Animal studies support that theory. GLP-1 drugs reduce inflammation in the brain and interfere with reward pathways linked to ...

After decades of setbacks, Alzheimer’s drug development is expanding beyond anti-amyloids, with a record number of trials and ...

Novo Nordisk's pipeline, especially the oral GLP-1 and Alzheimer’s trial, offers significant long-term upside. Click here to ...

Stores of glucose in the brain could play a much more significant role in the pathological degeneration of neurons than ...

Scientists have discovered that the metabolism of glycogen, a sugar stored in neurons, can protect the brain from Alzheimer's disease and cognitive decline.

Scientists have uncovered a surprising sugar-related mechanism inside brain cells that could transform how we fight Alzheimer’s and other dementias. It turns out neurons don’t just store sugar for ...

A new study from scientists at the Buck Institute for Research on Aging has revealed a surprising player in the battle ...

Employers are grappling with the ripple effect of an increasingly popular weight loss treatment. Pharmacy benefit leaders at Holmes Murphy share what to consider when evaluating GLP-1s for your ...

Have you or someone you love been diagnosed with Alzheimer’s disease? This clinical trial may be just what you.